These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21652149)

  • 1. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.
    Saijo N
    Cancer Treat Rev; 2012 Feb; 38(1):63-7. PubMed ID: 21652149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in early cancer drug development: limited utility.
    Glassman RH; Ratain MJ
    Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker research in breast cancer.
    Maxwell C
    Clin J Oncol Nurs; 2010 Dec; 14(6):771-83. PubMed ID: 21112854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF receptor in lung cancer: a successful story of targeted therapy.
    Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
    Saijo N
    Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological markers in lung cancer: A clinician's perspective.
    Tufman A; Huber RM
    Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.
    Riesterer O; Milas L; Ang KK
    J Clin Oncol; 2007 Sep; 25(26):4075-83. PubMed ID: 17827456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
    Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
    Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
    J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for breast cancer.
    Beenken SW; Bland KI
    Minerva Chir; 2002 Aug; 57(4):437-48. PubMed ID: 12145573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in clinical medicine.
    Chen XH; Huang S; Kerr D
    IARC Sci Publ; 2011; (163):303-22. PubMed ID: 22997869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for lung cancer: clinical uses.
    Greenberg AK; Lee MS
    Curr Opin Pulm Med; 2007 Jul; 13(4):249-55. PubMed ID: 17534168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of gene expression profiling in breast cancer.
    Sparano JA; Fazzari M; Kenny PA
    Surg Oncol Clin N Am; 2010 Jul; 19(3):581-606. PubMed ID: 20620929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.